Proof of Usefulness Report

Illimis Therapeutics

Analysis completed on 2/9/2026

+76
Proof of Usefulness Score
You're In Business

Illimis Therapeutics appears to be a legitimate South Korean biotech company (Series A funding ~$15M USD) working on high-potential Alzheimer's treatments. However, the submission itself contains critical credibility gaps, including blatant falsehoods regarding user traction ('most people have used my product') and exaggerated audience reach ('everyone'). While the scientific mission and market timing are excellent, the lack of verifiable commercial traction and the poor quality of the submission data significantly penalize the final score.

Ready to Compete for $150k+ in Prizes?

Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes

View All Reports

Score Breakdown

Real World Utility+26.12
Audience Reach Impact+1.00
Technical Innovation+14.85
Evidence Of Traction+13.00
Market Timing Relevance+9.50
Functional Completeness+0.25
Subtotal+64.72
Usefulness Multiplierx1.18
Final Score+76

Project Details

Project URL
illimistx.com
Description
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.

Algorithm Insights

Market Position
Growing utility with room for optimization
User Engagement
Documented reach suggests active user community
Technical Stack
Modern tech stack aligned with sponsor technologies

Recommendations to Increase Usefulness Score

Document User Growth

Provide specific metrics on user acquisition and retention rates

Showcase Revenue Model

Detail sustainable monetization strategy and current revenue streams

Expand Evidence Base

Include testimonials, case studies, and third-party validation

Technical Roadmap

Share development milestones and feature completion timeline